Familial hypercholesterolemia: genes and variants
Explore variant evidence for Familial hypercholesterolemia across 7 analyzed proteins (LDLR, PCSK9, APOB, APOE, GHR and 2 more). Linked ClinVar records include 682 pathogenic or likely pathogenic variants, 1,039 variants of uncertain significance and 346 with conflicting classifications.
Coverage includes proteins already analyzed in CATVariant, not every gene involved in this condition. Database links are associations, not an assessment of clinical gene–disease validity. Computable evidence prioritizes variants for expert review and does not reclassify them. Source labels are pooled across this disease family.
Data updated 2026-11-05. Automated aggregation, not a clinical review date.
Download variant evidence (CSV)
Genes linked to Familial hypercholesterolemia
LDLR: Low-density lipoprotein receptor
It removes ApoB-containing LDL particles from the circulation through receptor-mediated endocytosis, especially in hepatocytes. Loss-of-function variants are the most common cause of familial hypercholesterolemia and lead to lifelong LDL elevation and premature atherosclerotic disease.
668 ClinVar pathogenic / likely pathogenic and 843 uncertain variants in LDLR have source records linked to Familial hypercholesterolemia. Association strength is not clinical gene validity.
PCSK9: Proprotein convertase subtilisin/kexin type 9
By binding hepatic LDL receptors and promoting their lysosomal degradation, it reduces receptor recycling and raises circulating LDL cholesterol. Gain-of-function variants cause autosomal dominant hypercholesterolemia, whereas loss-of-function variants lower LDL cholesterol and cardiovascular risk.
8 ClinVar pathogenic / likely pathogenic and 412 uncertain variants in PCSK9 have source records linked to Familial hypercholesterolemia. Association strength is not clinical gene validity.
APOB: Apolipoprotein B-100
It provides the structural backbone for triglyceride-rich lipoproteins and LDL, while ApoB-100 also mediates LDL-receptor binding and clearance. Pathogenic variants can cause familial hypobetalipoproteinemia or defective ApoB-related hypercholesterolemia depending on their effect on particle assembly and receptor binding.
3 ClinVar pathogenic / likely pathogenic and 107 uncertain variants in APOB have source records linked to Familial hypercholesterolemia. Association strength is not clinical gene validity.
APOE: Apolipoprotein E
It redistributes cholesterol and other lipids between tissues by directing remnant lipoproteins to LDL-receptor-family members. The common epsilon4 isoform strongly increases late-onset Alzheimer disease risk and also influences plasma lipids and cardiovascular risk.
3 ClinVar pathogenic / likely pathogenic and 14 uncertain variants in APOE have source records linked to Familial hypercholesterolemia. Association strength is not clinical gene validity.
GHR: Growth hormone receptor
Its activation by growth hormone triggers JAK2-STAT signaling that promotes IGF-1 production, linear growth, and metabolic effects. Biallelic or dominant-negative loss-of-function variants can cause growth-hormone insensitivity, while activating alterations are rare.
0 ClinVar pathogenic / likely pathogenic and 6 uncertain variants in GHR have source records linked to Familial hypercholesterolemia. Association strength is not clinical gene validity.
ANGPTL3: Angiopoietin-related protein 3
It restrains lipoprotein and endothelial lipases, thereby increasing circulating triglyceride and HDL-cholesterol levels. Loss-of-function variants produce familial combined hypolipidemia and are associated with lower atherosclerotic cardiovascular risk, making the pathway a therapeutic target.
0 ClinVar pathogenic / likely pathogenic and 0 uncertain variants in ANGPTL3 have source records linked to Familial hypercholesterolemia. Association strength is not clinical gene validity.
HMGCR: 3-hydroxy-3-methylglutaryl-coenzyme A reductase
It controls the rate-limiting step of the mevalonate pathway and therefore strongly regulates endogenous cholesterol production. Statins lower LDL cholesterol by inhibiting this activity, causing the liver to increase LDL-receptor-mediated clearance from blood.
0 ClinVar pathogenic / likely pathogenic and 0 uncertain variants in HMGCR have source records linked to Familial hypercholesterolemia. Association strength is not clinical gene validity.
Weakly linked (only a few uncertain records): ABCA1 and G6PD.
Where Familial hypercholesterolemia variants cluster
- LDLR Binding to Getah virus E1-E2 spike glycoproteins (positions 146–233): 110 of 598 ClinVar pathogenic / likely pathogenic variants, 1.8× more than its size predicts (a length-based count, not a validated hotspot).
- LDLR EGF-like 2 (positions 354–393): 46 of 598 ClinVar pathogenic / likely pathogenic variants, 1.6× more than its size predicts (a length-based count, not a validated hotspot).
ClinVar pathogenic and likely pathogenic variants linked to Familial hypercholesterolemia
| Variant | Position | Protein part | Clinical label |
|---|---|---|---|
| LDLR A501V | 501 | LDL-receptor class B 3 | Pathogenic / likely pathogenic (★★★★) |
| APOE R154S | 154 | 4 | Pathogenic / likely pathogenic (★★★★) |
| LDLR D90G | 90 | LDL-receptor class A 2 | Pathogenic / likely pathogenic (★★★) |
| LDLR E101K | 101 | LDL-receptor class A 2 | Pathogenic / likely pathogenic (★★★) |
| LDLR D136N | 136 | LDL-receptor class A 3 | Pathogenic / likely pathogenic (★★★) |
| LDLR D139N | 139 | LDL-receptor class A 3 | Pathogenic / likely pathogenic (★★★) |
| LDLR D139E | 139 | LDL-receptor class A 3 | Pathogenic / likely pathogenic (★★★) |
| LDLR E140K | 140 | LDL-receptor class A 3 | Pathogenic / likely pathogenic (★★★) |
| LDLR C143Y | 143 | LDL-receptor class A 3 | Pathogenic / likely pathogenic (★★★) |
| LDLR S177L | 177 | LDL-receptor class A 4 | Pathogenic / likely pathogenic (★★★) |
| LDLR C184Y | 184 | LDL-receptor class A 4 | Pathogenic / likely pathogenic (★★★) |
| LDLR D221G | 221 | LDL-receptor class A 5 | Pathogenic / likely pathogenic (★★★) |
| LDLR C222F | 222 | LDL-receptor class A 5 | Pathogenic / likely pathogenic (★★★) |
| LDLR C222R | 222 | LDL-receptor class A 5 | Pathogenic / likely pathogenic (★★★) |
| LDLR D227E | 227 | LDL-receptor class A 5 | Pathogenic / likely pathogenic (★★★) |
| LDLR E228K | 228 | LDL-receptor class A 5 | Pathogenic / likely pathogenic (★★★) |
| LDLR C261Y | 261 | LDL-receptor class A 6 | Pathogenic / likely pathogenic (★★★) |
| LDLR D263N | 263 | LDL-receptor class A 6 | Pathogenic / likely pathogenic (★★★) |
| LDLR D266N | 266 | LDL-receptor class A 6 | Pathogenic / likely pathogenic (★★★) |
| LDLR C302Y | 302 | LDL-receptor class A 7 | Pathogenic / likely pathogenic (★★★) |
| LDLR D304Y | 304 | LDL-receptor class A 7 | Pathogenic / likely pathogenic (★★★) |
| LDLR D304N | 304 | LDL-receptor class A 7 | Pathogenic / likely pathogenic (★★★) |
| LDLR D304E | 304 | LDL-receptor class A 7 | Pathogenic / likely pathogenic (★★★) |
| LDLR C325Y | 325 | EGF-like 1 | Pathogenic / likely pathogenic (★★★) |
| LDLR S326C | 326 | EGF-like 1 | Pathogenic / likely pathogenic (★★★) |
| LDLR G335S | 335 | EGF-like 1 | Pathogenic / likely pathogenic (★★★) |
| LDLR G343D | 343 | EGF-like 1 | Pathogenic / likely pathogenic (★★★) |
| LDLR G343S | 343 | EGF-like 1 | Pathogenic / likely pathogenic (★★★) |
| LDLR C352Y | 352 | EGF-like 1 | Pathogenic / likely pathogenic (★★★) |
| LDLR C364R | 364 | EGF-like 2 | Pathogenic / likely pathogenic (★★★) |
| LDLR L385P | 385 | EGF-like 2 | Pathogenic / likely pathogenic (★★★) |
| LDLR A399D | 399 | LDL-receptor class B 1 | Pathogenic / likely pathogenic (★★★) |
| LDLR R406W | 406 | LDL-receptor class B 1 | Pathogenic / likely pathogenic (★★★) |
| LDLR R406P | 406 | LDL-receptor class B 1 | Pathogenic / likely pathogenic (★★★) |
| LDLR R406Q | 406 | LDL-receptor class B 1 | Pathogenic / likely pathogenic (★★★) |
| LDLR E408K | 408 | LDL-receptor class B 1 | Pathogenic / likely pathogenic (★★★) |
| LDLR D415H | 415 | LDL-receptor class B 1 | Pathogenic / likely pathogenic (★★★) |
| LDLR L426P | 426 | LDL-receptor class B 1 | Pathogenic / likely pathogenic (★★★) |
| LDLR V429M | 429 | LDL-receptor class B 1 | Pathogenic / likely pathogenic (★★★) |
| LDLR A431T | 431 | LDL-receptor class B 1 | Pathogenic / likely pathogenic (★★★) |
| LDLR W443C | 443 | LDL-receptor class B 2 | Pathogenic / likely pathogenic (★★★) |
| LDLR W443S | 443 | LDL-receptor class B 2 | Pathogenic / likely pathogenic (★★★) |
| LDLR G478R | 478 | LDL-receptor class B 2 | Pathogenic / likely pathogenic (★★★) |
| LDLR D482H | 482 | LDL-receptor class B 2 | Pathogenic / likely pathogenic (★★★) |
| LDLR D482N | 482 | LDL-receptor class B 2 | Pathogenic / likely pathogenic (★★★) |
| LDLR I488N | 488 | LDL-receptor class B 3 | Pathogenic / likely pathogenic (★★★) |
| LDLR D492H | 492 | LDL-receptor class B 3 | Pathogenic / likely pathogenic (★★★) |
| LDLR D492N | 492 | LDL-receptor class B 3 | Pathogenic / likely pathogenic (★★★) |
| LDLR V523M | 523 | LDL-receptor class B 3 | Pathogenic / likely pathogenic (★★★) |
| LDLR V523L | 523 | LDL-receptor class B 3 | Pathogenic / likely pathogenic (★★★) |
| LDLR A540T | 540 | LDL-receptor class B 4 | Pathogenic / likely pathogenic (★★★) |
| LDLR H583Y | 583 | LDL-receptor class B 5 | Pathogenic / likely pathogenic (★★★) |
| LDLR H583D | 583 | LDL-receptor class B 5 | Pathogenic / likely pathogenic (★★★) |
| LDLR H583R | 583 | LDL-receptor class B 5 | Pathogenic / likely pathogenic (★★★) |
| LDLR G592E | 592 | LDL-receptor class B 5 | Pathogenic / likely pathogenic (★★★) |
| LDLR G592R | 592 | LDL-receptor class B 5 | Pathogenic / likely pathogenic (★★★) |
| LDLR R595Q | 595 | LDL-receptor class B 5 | Pathogenic / likely pathogenic (★★★) |
| LDLR R595W | 595 | LDL-receptor class B 5 | Pathogenic / likely pathogenic (★★★) |
| LDLR F619L | 619 | LDL-receptor class B 6 | Pathogenic / likely pathogenic (★★★) |
| LDLR F619S | 619 | LDL-receptor class B 6 | Pathogenic / likely pathogenic (★★★) |
Showing 60 of 682.
Uncertain variants prioritized for review in Familial hypercholesterolemia
| Variant | Position | Protein part | Clinical label | Evidence |
|---|---|---|---|---|
| LDLR D492Y | 492 | LDL-receptor class B 3 | Conflicting reports (★) | +6: 7 other pathogenic changes within 3 positions; D492G at the same position is pathogenic; REVEL 0.983 |
| LDLR C296Y | 296 | LDL-receptor class A 7 | Conflicting reports (★) | +6: 4 other pathogenic changes within 3 positions; C296R at the same position is pathogenic; REVEL 0.952 |
| LDLR S226F | 226 | LDL-receptor class A 5 | Conflicting reports (★) | +6: 19 other pathogenic changes within 3 positions; S226C at the same position is pathogenic; REVEL 0.950 |
| LDLR W536C | 536 | LDL-receptor class B 4 | Conflicting reports (★) | +6: 5 other pathogenic changes within 3 positions; W536G at the same position is pathogenic; REVEL 0.864 |
| LDLR L682P | 682 | EGF-like 3 | Conflicting reports (★) | +6: 10 other pathogenic changes within 3 positions; L682F at the same position is pathogenic; REVEL 0.957 |
| LDLR Q366R | 366 | EGF-like 2 | Conflicting reports (★) | +6: 11 other pathogenic changes within 3 positions; Q366P at the same position is pathogenic; REVEL 0.955 |
| LDLR C39R | 39 | LDL-receptor class A 1 | Conflicting reports (★) | +6: 2 other pathogenic changes within 3 positions; C39F at the same position is pathogenic; REVEL 0.961 |
| LDLR M531T | 531 | LDL-receptor class B 4 | Conflicting reports (★) | +6: 4 other pathogenic changes within 3 positions; M531K at the same position is pathogenic; REVEL 0.931 |
| LDLR G676S | 676 | EGF-like 3 | Conflicting reports (★) | +6: 6 other pathogenic changes within 3 positions; G676C at the same position is pathogenic; REVEL 0.954 |
| LDLR H607Y | 607 | LDL-receptor class B 5 | Conflicting reports (★) | +6: 8 other pathogenic changes within 3 positions; H607R at the same position is pathogenic; REVEL 0.901 |
| LDLR D100V | 100 | LDL-receptor class A 2 | Conflicting reports (★) | +6: 4 other pathogenic changes within 3 positions; D100G at the same position is pathogenic; REVEL 0.881 |
| LDLR S444P | 444 | LDL-receptor class B 2 | Conflicting reports (★) | +6: 8 other pathogenic changes within 3 positions; S444F at the same position is pathogenic; REVEL 0.941 |
| LDLR C261R | 261 | LDL-receptor class A 6 | Conflicting reports (★) | +6: 7 other pathogenic changes within 3 positions; C261F at the same position is pathogenic; REVEL 0.970 |
| LDLR T621I | 621 | LDL-receptor class B 6 | Conflicting reports (★) | +6: 8 other pathogenic changes within 3 positions; T621R at the same position is pathogenic; REVEL 0.866 |
| LDLR D133N | 133 | LDL-receptor class A 3 | Conflicting reports (★) | +6: 14 other pathogenic changes within 3 positions; D133Y at the same position is pathogenic; REVEL 0.798 |
| LDLR L401H | 401 | LDL-receptor class B 1 | Conflicting reports (★) | +6: 7 other pathogenic changes within 3 positions; L401V at the same position is pathogenic; REVEL 0.952 |
| LDLR C270R | 270 | LDL-receptor class A 6 | Conflicting reports (★) | +6: 6 other pathogenic changes within 3 positions; C270S at the same position is pathogenic; REVEL 0.915 |
| LDLR S580T | 580 | LDL-receptor class B 5 | Conflicting reports (★) | +6: 14 other pathogenic changes within 3 positions; S580F at the same position is pathogenic; REVEL 0.845 |
| LDLR D170G | 170 | LDL-receptor class A 4 | Conflicting reports (★) | +6: 22 other pathogenic changes within 3 positions; D170E at the same position is pathogenic; REVEL 0.817 |
| LDLR L646I | 646 | LDL-receptor class B 6 | Conflicting reports (★) | +6: 2 other pathogenic changes within 3 positions; L646Q at the same position is pathogenic; REVEL 0.855 |
| LDLR T389M | 389 | EGF-like 2 | Conflicting reports (★) | +6: 4 other pathogenic changes within 3 positions; T389K at the same position is pathogenic; REVEL 0.810 |
| LDLR D168E | 168 | LDL-receptor class A 4 | Conflicting reports (★) | +6: 12 other pathogenic changes within 3 positions; D168A at the same position is pathogenic; REVEL 0.821 |
| LDLR D525E | 525 | LDL-receptor class B 3 | Conflicting reports (★) | +6: 3 other pathogenic changes within 3 positions; D525V at the same position is pathogenic; REVEL 0.845 |
| LDLR D304H | 304 | LDL-receptor class A 7 | Uncertain (★★★) | +6: 14 other pathogenic changes within 3 positions; D304Y at the same position is pathogenic; REVEL 0.990 |
| LDLR W483C | 483 | LDL-receptor class B 2 | Uncertain (★★★) | +6: 8 other pathogenic changes within 3 positions; W483R at the same position is pathogenic; REVEL 0.951 |
| LDLR R574C | 574 | LDL-receptor class B 5 | Uncertain (★★★) | +6: 6 other pathogenic changes within 3 positions; R574H at the same position is pathogenic; REVEL 0.967 |
| LDLR F282S | 282 | LDL-receptor class A 7 | Uncertain (★★★) | +6: 5 other pathogenic changes within 3 positions; F282L at the same position is pathogenic; REVEL 0.985 |
| LDLR G373S | 373 | EGF-like 2 | Uncertain (★) | +6: 8 other pathogenic changes within 3 positions; G373V at the same position is pathogenic; REVEL 0.952 |
| LDLR L479P | 479 | LDL-receptor class B 2 | Uncertain (★★★) | +6: 12 other pathogenic changes within 3 positions; L479Q at the same position is pathogenic; REVEL 0.949 |
| LDLR R574L | 574 | LDL-receptor class B 5 | Uncertain (★★★) | +6: 6 other pathogenic changes within 3 positions; R574H at the same position is pathogenic; REVEL 0.937 |
| LDLR G335D | 335 | EGF-like 1 | Uncertain (★★★) | +6: 8 other pathogenic changes within 3 positions; G335C at the same position is pathogenic; REVEL 0.857 |
| LDLR G335R | 335 | EGF-like 1 | Uncertain (★★★) | +6: 8 other pathogenic changes within 3 positions; G335C at the same position is pathogenic; REVEL 0.901 |
| LDLR S580C | 580 | LDL-receptor class B 5 | Uncertain (★★★) | +6: 14 other pathogenic changes within 3 positions; S580F at the same position is pathogenic; REVEL 0.880 |
| LDLR F114I | 114 | LDL-receptor class A 3 | Uncertain (★★) | +6: 5 other pathogenic changes within 3 positions; F114L at the same position is pathogenic; REVEL 0.919 |
| LDLR G323S | 323 | EGF-like 1 | Uncertain (★★★) | +6: 6 other pathogenic changes within 3 positions; G323C at the same position is pathogenic; REVEL 0.871 |
| LDLR S499C | 499 | LDL-receptor class B 3 | Uncertain (★★★) | +6: 5 other pathogenic changes within 3 positions; S499P at the same position is pathogenic; REVEL 0.811 |
| LDLR D221E | 221 | LDL-receptor class A 5 | Uncertain (★) | +6: 15 other pathogenic changes within 3 positions; D221V at the same position is pathogenic; REVEL 0.907 |
| LDLR G287S | 287 | LDL-receptor class A 7 | Uncertain (★★★) | +6: 9 other pathogenic changes within 3 positions; G287C at the same position is pathogenic; REVEL 0.902 |
| LDLR D651V | 651 | LDL-receptor class B 6 | Uncertain (★★★) | +6: 5 other pathogenic changes within 3 positions; D651Y at the same position is pathogenic; REVEL 0.793 |
| LDLR G207D | 207 | LDL-receptor class A 5 | Uncertain (★) | +6: 11 other pathogenic changes within 3 positions; G207C at the same position is pathogenic; REVEL 0.838 |
Which prediction tools work for Familial hypercholesterolemia
Observed separation of ClinVar pathogenic / likely pathogenic from benign / likely benign variants (AUROC × 100). This benchmark is not a clinical recommendation.
- MetaLR: 99 out of 100 (learned from overlapping clinical labels, so this is optimistic)
- EVE: 98 out of 100
- MetaSVM: 98 out of 100 (learned from overlapping clinical labels, so this is optimistic)
- REVEL: 98 out of 100 (learned from overlapping clinical labels, so this is optimistic)
- CATVariant: 98 out of 100 (learned from overlapping clinical labels, so this is optimistic)
- ESM1b (LLR): 97 out of 100
- MutPred: 96 out of 100 (learned from overlapping clinical labels, so this is optimistic)
- AlphaMissense: 95 out of 100
- PolyPhen-2: 90 out of 100 (learned from overlapping clinical labels, so this is optimistic)
- CADD: 87 out of 100
- SIFT: 85 out of 100
- phyloP: 78 out of 100
- SpliceAI: 55 out of 100 (learned from overlapping clinical labels, so this is optimistic)
- Pangolin: 44 out of 100 (learned from overlapping clinical labels, so this is optimistic)
Same protein, different disease
- Dyslipidemia also has ClinVar records linked to LDLR variants; they fall in the same places as the Familial hypercholesterolemia variants (32 pathogenic / likely pathogenic).
- Homozygous familial hypercholesterolemia also has ClinVar records linked to LDLR variants; they fall in the same places as the Familial hypercholesterolemia variants (26 pathogenic / likely pathogenic).
- Familial hypobetalipoproteinemia also has ClinVar records linked to APOB variants; they fall mostly in different places as the Familial hypercholesterolemia variants (7 pathogenic / likely pathogenic).
- Familial type 3 hyperlipoproteinemia also has ClinVar records linked to APOE variants; they fall mostly in different places as the Familial hypercholesterolemia variants (10 pathogenic / likely pathogenic).
Diseases related to Familial hypercholesterolemia
- Myocardial infarction, also linked to APOB, APOE, HMGCR, LDLR and 1 more
- Homozygous familial hypercholesterolemia, also linked to APOB, LDLR and PCSK9
- Alzheimer disease, also linked to APOE and HMGCR
- Type 2 diabetes mellitus, also linked to APOE and HMGCR
- Hyperlipoproteinemia, also linked to APOE and HMGCR
- Heart disease, also linked to LDLR and PCSK9
- Familial hypobetalipoproteinemia, also linked to ANGPTL3 and APOB
- Limb-girdle muscular dystrophy, also linked to HMGCR
- Age related macular degeneration, also linked to APOE
- Diabetes mellitus, also linked to APOE
- Dyslipidemia, also linked to LDLR
- Parkinson disease, also linked to HMGCR
Frequently asked questions
Which genes have records linked to Familial hypercholesterolemia?
This view contains 7 analyzed proteins: LDLR, PCSK9, APOB, APOE, GHR and 2 more. Links come from clinical records and association databases. They do not imply that every listed gene is a validated cause, and missing genes may not yet be analyzed.
What do the clinical classifications mean?
Linked records include 682 pathogenic or likely pathogenic variants, 1,039 variants of uncertain significance and 346 with conflicting classifications. Labels summarize source records; multi-condition records may not make a separate assertion for this disease. Check the original record and review status.
Does the evidence score change a VUS classification?
No. 46 VUS or conflicting variants reach the likely-pathogenic points range on the computable criteria available here. This is a research prioritization signal, not a clinical classification. Patient, family and other required evidence may be missing.
Can I download the variant evidence?
Download the CSV for all 2,161 variants in the selected disease scope, including clinical labels, review status, evidence criteria, predictor scores, functional measurements and population frequency where available.
About this data
Variant–disease links come from ClinVar, Open Targets and UniProt, pooled from eligible public CATVariant analyses of each human protein. Evidence scores use the ACMG/AMP Bayesian points scale with computable criteria only (position among known disease variants, rarity in gnomAD, calibrated predictors, deep mutational scanning); there is no family or patient data, so they prioritise variants for expert review and never classify them.
Download every variant as CSV · Browse all diseases · Methods · About the Center